Oncoc4, Inc.
Clinical trials sponsored by Oncoc4, Inc., explained in plain language.
-
New Dual-Action antibody targets tumors in early trial
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody designed to block two cancer growth signals (PD-1 and VEGF). The main goals are to find the safest dose and check for…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New cancer drug ONC-841 enters human testing for advanced tumors
Disease control Recruiting nowThis early-stage study tests a new drug called ONC-841 in about 72 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it helps control the cancer. Participants receive the drug through an IV, either alone or with…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New hope for lung cancer patients: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that got worse after immunotherapy. About 630 adults will be randomly assigned to receive either the new drug or chemo every three…
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC